A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis

Jin Endo, Motoaki Sano, Yasuhiro Izumiya, Kenichi Tsujita, Kazufumi Nakamura, Nobuhiro Tahara, Koichiro Kuwahara, Takayuki Inomata, Mitsuharu Ueda, Yoshiki Sekijima, Yukio Ando, Hiroyuki Tsutsui, Mitsuaki Isobe, Keiichi Fukuda

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel®, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.

Original languageEnglish
Pages (from-to)15-17
Number of pages3
JournalCirculation Journal
Volume84
Issue number1
DOIs
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis'. Together they form a unique fingerprint.

  • Cite this

    Endo, J., Sano, M., Izumiya, Y., Tsujita, K., Nakamura, K., Tahara, N., Kuwahara, K., Inomata, T., Ueda, M., Sekijima, Y., Ando, Y., Tsutsui, H., Isobe, M., & Fukuda, K. (2019). A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis. Circulation Journal, 84(1), 15-17. https://doi.org/10.1253/circj.CJ-19-0811